About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Wine Consumption and Glycemic Control | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT02518334

Wine Consumption and Glycemic Control

Many studies have reported that alcoholic beverage consumption, especially in the form of wine, reduces the risk of developing type 2 diabetes by as much as 40%. This association suggests that wine co...

Lead sponsor: University of Missouri-Columbia•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Missouri-Columbia

Our central hypothesis is that improvement in glycemic control by acute consumption of wine is mediated by ethanol. Subjects will have type 2 diabetes, pre-diabetes, and be sedentary and obese (BMI \>30). Subjects' glycemic control will be assessed by an oral glucose tolerance test (OGTT) at three different time points. One OGTT will occur shortly after consumption of red wine, the second after consumption of vodka containing the identical amount of ethanol as the wine treatment, and the third OGTT will occur shortly after consumption of an equal volume of water. The three OGTTs will be administered in random order.

Age

21 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•insulin resistant: diagnosed with pre-diabetes or fasting blood glucose \>/= 97 mg/dL
•T2D: diagnosed by primary care physician
•at risk of type 2 diabetes (obesity and physically inactive)
•age: 21-65

Exclusion Criteria

•smoking
•insulin use (other than once daily)
•physically active (\>30 mins aerobic exercise two days/week)
•recent (\>3 mo) changes in medication use or dose
•uncontrolled type two diabetes (HbA1C \>10%)
•advanced retinopathy or neuropathy
•pregnancy

Related studies

RECRUITINGPhase 1

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT07590193 · Diabetes Mellitus, Type 2

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035 · Diabetes Mellitus, Type 2, Depressive Symptoms, and more

Collection of Human Metabolic Tissues

NCT02861781 · Obesity, Insulin Resistance, and more

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT05692388 · Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, and more

Milk for Diabetes Prevention

NCT06513026 · Lactose Intolerance, Lactose Intolerant, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 26, 2017Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment14

Start dateMar 2012

Last updatedOct 26, 2017

Condition

Diabetes Mellitus, Type 2

Locations shown

University of Missouri

Columbia, Missouri

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 26, 2017Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions